A Putative Heparin Receptor in Smooth Muscle Cells
A Putative Heparin Receptor in Smooth Muscle Cells
批准号:
7303750
负责人:
LINDA J LOWE-KRENTZ
金额:
$23.33万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-06-01 至 2011-05-31
关键词:
AffectAnticoagulantsAreaArteriesAttentionBlood VesselsCell CycleCell NucleusCell ProliferationCellsCoagulantsCoagulation ProcessComplexCyclic AMP-Dependent Protein KinasesCyclic GMPCyclic GMP-Dependent Protein KinasesCyclin D1Cyclin-Dependent Kinase InhibitorCyclinsCytoplasmCytoskeletonDNA biosynthesisDNA chemical synthesisDataDisease ProgressionDrug usageEndocytosisEnzyme KineticsEnzymesEventFc ReceptorFocal AdhesionsG1 PhaseGene ExpressionGenesGenetic TranscriptionGrowth FactorHeparinIn VitroInflammationInflammatoryInvestigationKnowledgeLaboratoriesLeadLesionLightLinkLiteratureLocalizedMAPK14 geneMeasuresMethodsMicrofilamentsMitogen-Activated Protein KinasesMolecularN-terminalPathway interactionsPatternPhosphoric Monoester HydrolasesPhosphorylationPhosphotransferasesProcessProductionProteasome InhibitorProtein KinaseReceptor SignalingRelaxationResearchRoleSignal TransductionSignaling ProteinSmooth Muscle MyocytesStagingSystemTimeUbiquitinVascular DiseasesWestern BlottingWorkanalogcell growthcyclin G1designheparin receptorhuman MAPK14 proteinimprovedin vivoinhibitor/antagonistmulticatalytic endopeptidase complexp27 Cell Cycle Proteinp27 Enzyme Inhibitorprogramsreceptorrepairedresponsestress activated protein kinasetheoriestherapy designvasodilator-stimulated phosphoprotein
中文摘要
描述(由申请人提供):晚期血管疾病的特征是炎症变化,包括血管平滑肌细胞的过度生长,最终导致受影响动脉的阻塞。肝素是一种最著名的抗凝血剂,在体外和选定的体内研究中也显示出减缓平滑肌细胞生长的作用。肝素对血管平滑肌细胞的作用有几种理论解释,包括肝素与生长因子的相互作用、肝素受体和肝素的内吞作用以改变转录。PI的研究小组先前在血管细胞上发现了一种假定的肝素受体和抗受体抗体,这种抗体模拟肝素在血管平滑肌细胞中阻断DNA合成和降低ERK激活的功能。来自PI实验室的数据表明,在肝素诱导的ERK活性和DNA合成降低中,这种受体和信号转导涉及cGMP的产生、cGMP敏感蛋白激酶(PKG)的激活和特定双功能磷酸酶MKP1的合成。拟议的研究将扩大初步结果,表明Raf活性也会因肝素治疗而降低,并将证实肝素通过受体和PKG引起这种活性降低。肝素通过PKG途径对平滑肌细胞增殖的影响将涉及评估肝素对细胞周期蛋白/细胞周期蛋白激酶抑制剂水平和使用cGMP模拟物和PKG抑制剂合成的细胞周期蛋白D (G1期细胞周期蛋白)的影响。来自PI实验室的其他结果表明,活性JNK和p38应激激活蛋白激酶的一个子集的细胞骨架定位以及肝素降低JNK和p38激活的能力(通过western blotting评估)。拟议的研究将确定肝素是否也导致细胞骨架相关的JNK和p38以及细胞质中发现的效应物的活性降低,或者肝素的作用是否仅限于MKP1所在的细胞核。为了进一步评估肝素治疗通过PKG激活cGMP信号的程度,将评估已知的PKG靶点,如VASP和PAK1,以确定它们是否在肝素治疗后被特异性磷酸化,就像它们在NO或PKG酶的人工激活剂增加后一样,并评估基因表达共同变化的可能性。在PI实验室获得的初步结果表明,肝素治疗后PKG水平降低,表明PKG降解可能是由肝素信号传导和PKG激活诱导的。这种可能性将涉及到使用蛋白酶体抑制剂和检测与PKG相关的泛素的方法。最后,本研究将继续致力于分离肝素受体并获得有助于基因鉴定的序列信息。总之,提出的研究将证实肝素受体在肝素诱导的血管平滑肌细胞变化中的重要性,并将为理解肝素如何改变敏感的血管平滑肌细胞提供重大进展。血管中最复杂的信息系统之一是控制细胞生长和分裂的系统,它可以导致损伤修复,当过度活跃时,就会导致血管疾病。这项拟议的研究继续了PI实验室的一项调查模式,重点是了解导致细胞生长的信息传递通常被关闭的方式,重点是抗凝血分子肝素。在分子水平上更好地理解这些负面途径,包括肝素开启的途径,以及已知的参与降低血管张力的蛋白激酶G,将有助于设计更好的血管疾病治疗方法。
英文摘要
DESCRIPTION (provided by applicant): Late stage vascular disease is characterized by inflammatory changes including the overgrowth of vascular smooth muscle cells which eventually contribute to blocking of affected arteries. Heparin is best known as an anticoagulant that has also been shown to slow smooth muscle cell growth in vitro and in selected in vivo studies. Heparin effects on vascular smooth muscle cells have been explained by several theories including heparin interactions with growth factors, heparin receptors and endocytosis of heparin to alter transcription. The PI's research group previously identified a putative heparin receptor on vascular cells and anti-receptor antibodies that mimic heparin functions in blocking DNA synthesis and decreasing ERK activation in vascular smooth muscle cells. Data from the PI's laboratory implicate this receptor and signal transduction involving cGMP production, the activation of cGMP sensitive protein kinase (PKG) and synthesis of a specific dual function phosphatase, MKP1, in heparin induced decreases in ERK activity and DNA synthesis. The proposed research will expand on preliminary results indicating Raf activity is also decreased in response to heparin treatment and will confirm that heparin works through the receptor and PKG to cause this decreased activity. Confirmation that the effects of heparin on smooth muscle cell proliferation occur through the PKG pathway will involve evaluating heparin effects on cyclin/cyclin kinase inhibitor level and cyclin D (G1 phase cyclin) synthesis using cGMP mimics and PKG inhibitors. Additional results from the PI's laboratory demonstrate cytoskeletal localization of a subset of active JNK and p38 stress activated protein kinase enzymes and the ability of heparin to decrease activation of JNK and p38 as assessed by western blotting. Proposed research will determine whether heparin also results in decreased activity of the cytoskeletal associated JNK and p38 and effectors found in the cytoplasm, or whether heparin effects are restricted to the nucleus where the MKP1 resides. To further evaluate the extent to which heparin treatment activates cGMP signaling through PKG, known PKG targets such as VASP and PAK1 will be evaluated to determine whether they are specifically phosphorylated in response to heparin treatment as they are after increases in NO or artificial activators of the PKG enzyme and the possibility of a shared set of changes in gene expression will be evaluated. Preliminary results obtained in the PI's laboratory indicate that PKG levels decrease after heparin treatment suggesting that PKG degradation might be induced by heparin signaling and PKG activation. The possibility that this occurs will involve use of proteasome inhibitors and methods to detect ubiquitin linked to PKG. Finally, this study will continue work aimed at isolating the heparin receptor and obtaining sequence information that will facilitate gene identification. Together, the proposed studies will confirm the importance of the heparin receptor in heparin induced changes in vascular smooth muscle cells and will provide a significant advancement in understanding of how heparin alters sensitive vascular smooth muscle cells. One of the most complicated informational systems in blood vessels is that which controls cell growth and division that can lead both to damage repair, and when over active, to vascular disease. The proposed research continues a pattern of investigation in the PI's laboratory focused on understanding the way in which the information transfer leading to cell growth is normally turned off with a focus on the anti-coagulant molecule heparin. A better understanding of these negative pathways at the molecular level, including the pathway turned on by heparin and following through protein kinase G already known for its involvement in reducing blood vessel tension, will be helpful in designing improved treatments for vascular disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PUTATIVE HEPARIN RECEPTOR IN SMOOTH MUSCLE CELLS
-
批准号:2724190
-
项目类别:
-
资助金额:$11.51万
-
财政年份:1999
-
负责人:LINDA J LOWE-KRENTZ
-
依托单位:
A Putative Heparin Receptor in Smooth Muscle Cells
-
批准号:6503770
-
项目类别:
-
资助金额:$14.51万
-
财政年份:1995
-
负责人:LINDA J LOWE-KRENTZ
-
依托单位:
A Heparin Receptor in Vascular Cells
-
批准号:10513384
-
项目类别:
-
资助金额:$47.72万
-
财政年份:1995
-
负责人:LINDA J LOWE-KRENTZ
-
依托单位:
PUTATIVE HEPARIN RECEPTOR IN SMOOTH MUSCLE CELLS
-
批准号:2232588
-
项目类别:
-
资助金额:$11.7万
-
财政年份:1995
-
负责人:LINDA J LOWE-KRENTZ
-
依托单位:
A Putative Heparin Receptor in Smooth Muscle Cells
-
批准号:8101456
-
项目类别:
-
资助金额:$45.81万
-
财政年份:1995
-
负责人:LINDA J LOWE-KRENTZ
-
依托单位:
HEPARAN SULFATE EFFECTS ON ENDOTHELIAL CELL BEHAVIOR
-
批准号:3440004
-
项目类别:
-
资助金额:$7.98万
-
财政年份:1987
-
负责人:LINDA J LOWE-KRENTZ
-
依托单位:
海外基金